Core Viewpoint - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3]. Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies [4]. - The company holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4]. - Tyligand has not yet received any marketing approval for its candidate drugs and has not generated any revenue from product sales [4]. - The company is headquartered in Suzhou and employs a total of 64 staff, with 49 in research and development [4]. Shareholding Structure - Key shareholders include Dr. Tony Yantao Zhang, Dr. Boyu Zhong, Dr. Zhong-Yin Zhang, and Tyligand Holdings, collectively holding 24.01% of the issued shares [4]. - Dr. Tony Yantao Zhang directly holds approximately 0.35%, while Tyligand Holdings holds about 23.66%, with ownership distributed among the founders [4]. Management Team - Dr. Tony Yantao Zhang, 64, is the Chairman and CEO, responsible for overall management and strategic planning [5]. - Dr. Boyu Zhong, 63, serves as the Executive Director and President, leading research and development efforts [6]. Financial Performance - The company's revenue for 2023, 2024, and the first nine months of 2025 is projected to be 7.856 million, 1.506 million, and 11.358 million respectively, with losses of 70.461 million, 28.354 million, and 123 million [7]. - Revenue sources include providing research and development services and intellectual property licensing [7].

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, marking its largest strategic investment since entering the market in 1993, aimed at expanding its pharmaceutical production and R&D footprint [2][4] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery, clinical development to manufacturing, enhancing AstraZeneca's capabilities in cell therapy and antibody-drug conjugates [4][5] - The investment will significantly deepen AstraZeneca's R&D presence in China, linking over 500 clinical hospitals with its global strategic R&D centers in Beijing and Shanghai [4][5] - AstraZeneca's collaboration with CSPC Pharmaceutical Group could reach up to 18.5 billion USD (approximately 128.5 billion RMB), with an initial payment of 1.2 billion USD (approximately 8.4 billion RMB) [3][5] Group 2: Market Dynamics - China's pharmaceutical market is undergoing structural changes, with a record 76 innovative drugs approved by the National Medical Products Administration in 2025, indicating a trend towards diversified innovative therapies [3][6] - Approximately one-third of global licensing transactions are related to Chinese biopharmaceutical companies, with over 30% of clinical trials in cutting-edge fields like cell therapy and ADCs occurring in China [3][6] Group 3: Strategic Partnerships - AstraZeneca has formed partnerships with leading biotech companies in China, aiming to leverage local innovations and enhance global supply chains [5][6] - The company has engaged in 17 licensing collaborations with 15 Chinese partners since 2023, with contract values exceeding 10 billion USD in 2025 alone [5][6] Group 4: Innovation and Development - The investment aligns with China's "Healthy China 2030" initiative, focusing on improving disease prevention, early screening, and accessibility of innovative drugs [10][12] - AstraZeneca's R&D pipeline in China has grown significantly, with over 200 projects, and is expected to yield around 20 new drug approvals by 2030 [7][9] Group 5: Industry Impact - AstraZeneca's investment reflects the ongoing opening of the Chinese pharmaceutical market, supported by favorable policies and reforms that enhance the R&D environment [7][10] - The company has invested in 31 Chinese innovative enterprises through its medical industry fund, facilitating 17 global licensing collaborations worth over 13.7 billion USD [9][10]

Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. has received acceptance for its drug application for a powder oral solution of Ammonium Pentanoate Hydrochloride, aimed at visualizing malignant tissues during surgery for adult patients with high-grade malignant glioma [1] Group 1 - The drug application was accepted by the National Medical Products Administration, indicating progress in the regulatory process [1] - The clinical trial application for the drug was accepted in December 2023, with verification clinical research set to start in June 2024 [1] - The clinical research for the drug has been completed, leading to the recent acceptance of the drug registration application [1]

智通财经APP获悉，据港交所1月30日披露，征祥医药(南京)集团股份有限公司(以下简称"征祥医药")向港交所主板递交上市申请，中金公司为其独家保荐 人。 | 编纂]的[编纂]數目 | : [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | | 编纂 數目 " | [编纂]股H股(可予[编纂]) | | [编纂]數目 ። | [编纂]股H股(可予[编纂]及視乎[编纂]行使與否 | | 向定) | | | 最高 编纂 : | 每股H股[編纂]港元,另加1.0%經紀佣金、 | | | 0.0027%證監會交易徵費、0.00015%會財局 | | | 交易徵費及0.00565%聯交所交易費(須於申 | | | 請時以港元繳足,多繳股款可予退還) | | 面值 : | 每股H股人民幣0.10元 | | 编纂 : 编纂 | | 公司简介 据招股书，征祥医药是一家处于商业化阶段的生物制药公司，致力于发现、开发及商业化创新疗法，以解决病毒性传染病、肿瘤学及炎症性疾病领域未被 满足的医疗需求。 公司的核心产品玛硒洛沙韦片为靶向流感病毒聚合酶酸性蛋白(「PA」)核酸内切酶的抑制剂，已于2025年7月获得国 ...

1月30日，据港交所官网，征祥医药（南京）集团股份有限公司（下称"征祥医药"）递交主板上市申请。该公司核心产品刚于2025年10月上市，仍处于市 场爬升阶段，资产负债率高达416%。 招股书介绍，征祥医药的历史可追溯至2018年，是一家处于商业化阶段的生物制药公司，致力于发现、开发及商业化创新疗法，以解决病毒性传染病、肿 瘤学及炎症性疾病领域未被满足的医疗需求。 公司的核心产品玛硒洛沙韦片为靶向流感病毒聚合酶酸性蛋白（「PA」）核酸内切酶的抑制剂，已于2025年7月获得国家药监局用于治疗成人流感的新药 申请（「NDA」）批准，且正将其适应症扩展至青少年患者及暴露后预防领域。 | 截至12月31日 | | | | --- | --- | --- | | 止年度 | 截至9月30日止九個月 | | | 2024年 | 2024年 | 2025年 | | 人民幣千元 | 人民幣千元 (主织定:4) | 人民幣千元 | | 收入 | | | 355 | | --- | --- | --- | --- | | 銷售成本 . | = | | - | | 毛利 | - | - | 355 | | 其他收入 | 26.598 ...

Core Viewpoint - Company Kexing Pharmaceutical (科兴制药) is expected to achieve a net profit of approximately 135 million to 175 million yuan in 2025, representing a year-on-year increase of 328.83% to 455.89% compared to the previous year, driven by its "innovation + internationalization" strategy [1] Group 1: Financial Performance - The projected net profit for 2025 is estimated to be between 135 million and 175 million yuan, an increase of 103.52 million to 143.52 million yuan from the previous year [1] Group 2: Strategic Focus - Kexing Pharmaceutical has differentiated its innovation drug pipeline by focusing on three key areas: oncology, autoimmune diseases, and metabolic diseases, which collectively account for 32.2% of the global pharmaceutical market and show significant growth potential [2] - The oncology drug market is expected to grow from 253.3 billion USD in 2024 to 419.8 billion USD by 2030, with a compound annual growth rate of 8.8% [2] Group 3: Product Development - The GB18 injection, targeting GDF-15, is advancing to fill a significant market gap in treating cancer cachexia, with clinical trial approvals from both the FDA and the National Medical Products Administration [2] - Kexing is also developing innovative pipelines for autoimmune diseases, including the GB24 project targeting dual pathways for inflammatory bowel disease and the GB19 project for systemic lupus erythematosus [3] Group 4: AI Integration - In March 2025, Kexing Pharmaceutical entered a strategic partnership with Baidu Biotechnology to leverage AI technology in the development of large molecule drugs for oncology and autoimmune diseases [3] Group 5: International Expansion - Kexing has established a comprehensive global market network covering around 70 countries, with significant sales performance of its core products, including EPOSINO, which leads the market in export volume among similar products [4] - The company has successfully registered and commercialized multiple biopharmaceuticals in Southeast Asia, Latin America, and the Middle East, demonstrating its robust internationalization efforts [4]

Core Viewpoint - The company, Sinovac Biotech Ltd., is expected to achieve a significant increase in net profit for 2025, projecting between 135 million to 175 million yuan, representing a year-on-year growth of 328.83% to 455.89% in a challenging biopharmaceutical industry environment [1] Group 1: Innovation Pipeline Breakthroughs - The impressive growth in performance is attributed to the company's sustained focus on innovation and internationalization, with multiple products in the pipeline showing potential for "first-in-class" (FIC) or "best-in-class" (BIC) status [2][3] - The GB18 injection targeting GDF-15 for cancer cachexia is highlighted for its unique design and significant clinical results, having received clinical trial approvals from both the FDA and NMPA, positioning it as a leading candidate in its category [2] - The company is also advancing projects targeting autoimmune diseases, such as GB24 for inflammatory bowel disease, which aims to address dual targets for enhanced treatment efficacy, showcasing its commitment to innovation [3] Group 2: Internationalization and Revenue Growth - The company's international revenue has seen substantial growth, evolving from simple product exports to a replicable "platform-based internationalization" model, which is now in a phase of scaling [4] - Sinovac's global market presence has expanded to approximately 70 countries, with notable success in the EU market, where a key product, albumin paclitaxel, is expected to gain market approval, significantly contributing to revenue [4] - This platform model addresses critical challenges faced by smaller pharmaceutical companies in international markets, providing a reference for enhancing competitiveness in the biopharmaceutical industry [4] Group 3: Strategic Focus and Future Outlook - The biomanufacturing sector is recognized as a strategic emerging industry in China, with ongoing policy support, which will further accelerate the global clinical development of the company's core FIC/BIC pipelines [5] - The company aims to leverage technological upgrades to enhance product capabilities and drive sustained value creation through global operations [5]

证券代码：688076 证券简称：ST诺泰 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 二、上年同期业绩情况 2024年度，公司利润总额：43,850.42万元；归属于母公司所有者的净利润：40,439.00万元；归属于母公 司所有者的扣除非经常性损益的净利润：40,782.21万元；基本每股收益：1.88元/股。 三、本期业绩变化的主要原因 （一）报告期内，公司整体销售收入增长，但受行业价格波动影响及公司固定成本增加，导致公司毛利 率水平同比有所下降。 （二）报告期内，公司根据《企业会计准则》等有关要求，对相关资产进行减值测试后，对部分资产计 提减值准备，对公司本期业绩产生影响。 （二）业绩预告情况 （1）经财务部门初步测算，公司预计2025年年度实现营业收入人民币190,000万元到200,000万元，与上 年同期（法定披露数据）相比，将增加27,519.81万元到37,519.81万元，同比增加16 ...

证券代码：688399 证券简称：硕世生物 公告编号：2026-004 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ?经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-2,940万元到-4,400万元，与 上年同期（法定披露数据）相比，将扩大亏损2,739.83万元到4,199.83万元。 ?预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元到-12,280万元，与上年 同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 一、本期业绩预告情况 （3）本次业绩预告未经审计。 二、上年同期业绩情况 （一）2024年度公司实现利润总额为418.72万元。归属于母公司所有者的净利润为-200.17万元。归属于 母公司所有者的扣除非经常性损益的净利润为-7,183.71万元。 （二）2024年度基本每股收益为-0.02元(该数据为追溯调整后金额，公司于2025年6月实施2024年度权益 分派，以资本公积金向全体股东每10股转增4.8股， ...

（1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润为13,500万元至17,500万元，与上年同期（法定披露数据）相比，将增加 10,352万元至14,352万元，同比增加328.83%至455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为5,000万元至7,000万元，与上年同期（法 定披露数据）相比，将增加1,475万元至3,475万元，同比增加41.83%至98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 证券代码：688136 证券简称：科兴制药 公告编号：2026-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 除此之外，公司不存在其他影响本次业绩预告内容准确性的重大不确定因素。 五、其他说明事项 以上预告数据仅为初步核算数据，具体准确的财务数据以公司正式披露的经审计后的 ...